Cambridge Bioscience is delighted to announce a new distribution partnership with APExBIO Technology LLC, following our recent acquisition of Stratech Scientific. This extends the availability of APExBIO’s extensive portfolio of high-quality research reagents for scientists across the UK and Ireland.
The partnership will provide researchers with streamlined access to a broad range of products, including small-molecule inhibitors, compound libraries, peptides, assay kits, enzymes, fluorescent labels and mRNA research products. These solutions support a wide variety of applications across life science research and drug discovery.
APExBIO is a US-based supplier of quality-verified reagent solutions, providing comprehensive product validation where every lot ships with a certificate of analysis (COA) that includes HPLC, MS and NMR analysis data to ensure lot to lot reproducibility . The company serves scientists and research institutions worldwide, with particular expertise in oncology, immunology, neuroscience, epigenetics and broader life science research areas. APExBIO is dedicated to advancing scientific discovery and accelerating the translation of research from bench to application.
Through this partnership, Cambridge Bioscience will provide local technical support, product expertise and customer service, helping researchers across the UK and Ireland maximise the value of APExBIO’s trusted portfolio and accelerate their research programmes.
This collaboration further strengthens Cambridge Bioscience’s commitment to supporting the life science community with innovative, high-quality tools and technologies that enable scientific progress, discovery and innovation.
Learn more about APExBIO’s portfolio or contact our APExBIO specialists.